NCT03239379View on ClinicalTrials.gov

A Multiple-Dose Study of Intravenous BNZ132-1-40 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 30, 2017

Primary Completion Date

February 15, 2018

Study Completion Date

March 8, 2018

Conditions
Safety and Tolerability in Healthy Subjects
Interventions
DRUG

BNZ132-1-40

Injectable peptide antagonist of IL-2, IL-9 and IL-15

DRUG

Placebo

Normal Saline

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Bioniz Therapeutics

INDUSTRY

NCT03239379 - A Multiple-Dose Study of Intravenous BNZ132-1-40 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter